We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter) (AcQForce AFL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT04658940
Recruitment Status : Active, not recruiting
First Posted : December 9, 2020
Last Update Posted : August 3, 2022
Information provided by (Responsible Party):
Acutus Medical

Brief Summary:
The Acutus Medical AcQForce Flutter clinical study is a prospective, multi-center, non-randomized global study designed to demonstrate the safety and effectiveness of the AcQBlate Force Sensing Ablation System in the ablation management of symptomatic cavotricuspid isthmus dependent atrial flutter.

Condition or disease Intervention/treatment Phase
Typical Atrial Flutter Device: AcQBlate® Force Sensing Ablation System Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: AcQBlate Force Sensing Ablation System US IDE for Atrial Flutter (AcQForce Flutter)
Actual Study Start Date : March 25, 2021
Actual Primary Completion Date : May 12, 2022
Estimated Study Completion Date : September 28, 2022

Arm Intervention/treatment
Experimental: Non-randomized
All subjects with typical atrial flutter will undergo percutaneous catheter ablation of the cavotricuspid isthmus using the AcQBlate Force Sensing System.
Device: AcQBlate® Force Sensing Ablation System
Percutaneous catheter ablation of the cavotricuspid isthmus
Other Names:
  • AcQBlate Force Sensing System
  • AcQBlate Force

Primary Outcome Measures :
  1. Subjects free from procedure/device related Serious Adverse Events (SAEs) [ Time Frame: 7 days ]
    Subjects free from a composite list of pre-specified procedure/device related Serious Adverse Events (SAEs)

  2. Subjects achieving acute procedural success [ Time Frame: 20 minutes post ablation ]
    Acute procedural success is defined as the demonstration of bidirectional cavotricuspid isthmus block at least 20 minutes following the last radiofrequency application at the cavotricuspid isthmus with the investigational System.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Subjects are clinically indicated for de novo catheter ablation of typical atrial flutter.
  2. At least one (1) documented episode of typical atrial flutter within 180 days (6 months) prior to enrollment, documented by 12-lead ECG.
  3. Age 18 years or older at time of consent.
  4. Subjects are willing and able to provide written informed consent to participate in the study and agree to comply with all follow-up visits and evaluations.

Exclusion Criteria:

  1. In the opinion of the Investigator, any contraindication to the planned atrial ablation, including contraindications to anticoagulation therapy and any other significant uncontrolled or unstable medical condition (e.g. sepsis, acute metabolic illness, chronic kidney disease).
  2. Inability to entrain CTI dependent AFL by standard pacing at procedure.
  3. Any prior right atrial cavotricuspid isthmus ablation.
  4. Any cardiac ablation for non-atrial flutter arrhythmias within 90 days prior to enrollment.
  5. Any patient scheduled or anticipating an AF ablation within the follow-up period.
  6. Use of amiodarone within 120 days prior to procedure.
  7. Cardiac surgery within 60 days prior to enrollment.
  8. ST-elevation myocardial infarction (STEMI) within 60 days prior to enrollment
  9. Current unstable angina.
  10. Documented atrial or ventricular tumors, clots, thrombus, within 30-days prior to enrollment.
  11. Any history of a known hematologic disorder (bleeding/clotting).
  12. Implantation of permanent leads of an implantable device in or through the right atrium within 90-days prior to enrollment.
  13. Subjects with New York Heart Association (NYHA) Class IV heart failure within 6-months prior to enrollment.
  14. Subjects with an ejection fraction less than 30% within 90 days of enrollment.
  15. Percutaneous Transluminal Coronary Angioplasty (PTCA) within 30-days of enrollment.
  16. Clinically significant structural heart disease (including moderate to severe tricuspid valve regurgitation, tricuspid valve stenosis, or tricuspid valve replacement; Ebstein's anomaly, or other congenital heart disease) that would preclude catheter introduction and placement, as determined by the Investigator.
  17. Any cerebral ischemic/infarct event (excluding transient ischemic attacks) within 180 days prior to enrollment.
  18. Body Mass Index (BMI) >42 kg/m2.
  19. International Normalized Ratio (INR) > 3.
  20. Severe uncontrolled systemic hypertension (systolic pressure > 240 mm Hg) within the last 30-days.
  21. Women who are pregnant or plan to become pregnant within the course of their participation in the investigation.
  22. Current enrollment in any other study protocol where testing or results from the study may interfere with the procedure or outcome measurements for this study.
  23. Any other condition that, in the judgment of the Investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a life expectancy of less than two years, extensive travel away from the research center).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04658940

Layout table for location information
United States, Florida
Celebration Hospital
Orlando, Florida, United States, 32803
United States, Kentucky
Baptist Lexington Medical Center
Lexington, Kentucky, United States, 40503
United States, Maryland
Adventist Healthcare | White Oak Medical Center
Silver Spring, Maryland, United States, 20904
United States, Ohio
ProMedica Physician Cardiology
Toledo, Ohio, United States, 43615
Sponsors and Collaborators
Acutus Medical
Layout table for additonal information
Responsible Party: Acutus Medical
ClinicalTrials.gov Identifier: NCT04658940    
Obsolete Identifiers: NCT04657055
Other Study ID Numbers: CLP-21
First Posted: December 9, 2020    Key Record Dates
Last Update Posted: August 3, 2022
Last Verified: August 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Flutter
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes